Micromet drug sees leukemia remission in Phase II trial

06/12/2011 | Bloomberg

Interim results of a midstage study indicate that blinatumomab, an investigational drug from Micromet, produced complete remission in nine of 12 patients whose acute lymphoblastic leukemia had relapsed after conventional treatment. The positive data could bring accelerated FDA approval, an analyst said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health